Broad-band ultraviolet B phototherapy in zoster patients may reduce the incidence and severity of postherpetic neuralgia

Photodermatology Photoimmunology and Photomedicine

Volumn 22, Issue 5, 2006, Pages 232-237

  Hadi Aziz Jalali, Mir ^a   Ansarin, Habib ^a   Soltani Arabshahi, Razieh ^a  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Phototherapy; Postherpetic neuralgia; Prevention; UVB; Zoster

Indexed keywords

ACICLOVIR; AMITRIPTYLINE; ANALGESIC AGENT; PARACETAMOL; ZINC OXIDE;

ADULT; AGED; ANALGESIA; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATOME; DISEASE SEVERITY; DOSE RESPONSE; FEMALE; FOLLOW UP; HERPES ZOSTER; HUMAN; IMMUNOMODULATION; INCIDENCE; INTRACTABLE PAIN; MALE; OPEN STUDY; PAIN ASSESSMENT; PHOTOTHERAPY; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; RADIATION DOSE; RATING SCALE; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; ULTRAVIOLET B RADIATION;

ACYCLOVIR; ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; COMBINED MODALITY THERAPY; FEMALE; HERPES ZOSTER; HUMANS; MALE; MIDDLE AGED; NEURALGIA, POSTHERPETIC; PAIN MEASUREMENT; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; ULTRAVIOLET THERAPY;

EID: 33748255257     PISSN: 09054383     EISSN: 16000781     Source Type: Journal    
DOI: 10.1111/j.1600-0781.2006.00236.x     Document Type: Article

References (28)

1. Desmond RA, Weiss HL, Arani RB, et al. Clinical applications for change-point analysis of herpes zoster pain. J Pain Symptom Manage 2002; 23: 510-516.
2. Kost RG, Straus SE. Post-herpetic neuralgia: Pathogenesis, treatment and prevention. N Engl J Med 1996; 335: 32-42.
3. Portenoy RK, Duma C, Foley KM. Acute herpetic and postherpetic neuralgia: Clinical review and current management. Ann Neurol 1986; 20: 651-664.
4. Nurmikko T, Bowsher D. Somatosensory findings in postherpetic neuralgia. J Neurol Neurosurg Psychiatry 1990; 53: 135-141.
5. Bowsher D. Post-herpetic neuralgia in older patients. Incidence and optimal treatment. Drugs Aging 1994; 5: 411-418.
6. Choo PW, Galil K, Donahue JG, et al. Risk factors for postherpetic neuralgia. Arch Intern Med 1997; 157: 1217-1224.
7. Dworkin RH, Schmader. KE. Treatment and prevention of postherpetic neuralgia. Clin Infect Dis 2003; 36: 877-882.
8. Jackson JL, Gibbons R, Meyer G, Inouye L. The effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia. A meta-analysis. Arch Intern Med 1997; 157: 909-912.
9. Calza AM, Schmied E, Harms M. Systemic corticosteroids do not prevent postherpetic neuralgia. Dermatology 1992; 184: 314-316.
10. Opstelten W, van Wijck AJM, Stolker RJ. Interventions to prevent postherpetic neuralgia: Cutaneous and percutaneous techniques. Pain 2004; 107: 202-206.
11. Bowsher D. The effects of pre-emptive treatment of postherpetic neuralgia with amitriptyline: A randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage 1997; 13: 327-331.
12. Schon F, Mayer ML, Kelly JS. Pathogenesis of post-herpetic neuralgia. Lancet 1987; 2: 366-368.
13. Alper BS, Lewis PR. Does treatment of acute herpes zoster prevent or shorten postherpetic neuralgia? J Fam Pract 2000; 49: 255-264.
14. Dworkin RH. Overview of neuropathic pain: Syndromes, symptoms, signs, and several mechanisms. Clin J Pain 2002; 18: 343-349.
15. Zak-Prelich M, McKenzie RC, Sysa-Jedrzejowska A, Norval M. Local immune responses and systemic cytokine responses in zoster: Relationship to the development of postherpetic neuralgia. Clin Exp Immunol 2003; 131: 318-323.
16. Junger H, Sorkin LS. Nociceptive and inflammatory effects of subcutaneous TNFalpha. Pain 2000; 85: 145-151.
17. Misery L. Langerhans cells in the neuro-immuno-cutaneous system. J Neuroimmunol 1998; 89: 83-87.
18. Oaklander AL, Stocks EA, Mouton PR. Number of Langerhans immune cells in painful and non-painful human skin after shingles. Arch Dermatol Res 2003; 294: 529-535.
19. Granstein RD, Matsui MS. UV radiation-induced immunosuppression and skin cancer. Cutis 2004; 74: 4-9.
20. Ito T, Seo N, Yagita H, et al. Alterations of immune functions in barrier disrupted skin by UVB irradiation. J Dermatol Sci 2003; 33: 151-159.
21. Mahalingam R, Wellish M, Brucklier J, Gilden DH. Persistence of varicella-zoster virus DNA in elderly patients with postherpetic neuralgia. J Neurovirol 1995; 1: 130-133.
22. Hayward AR, Cosyns M, Jones M, et al. Cytokine production in varicella-zoster virus-stimulated cultures of human blood lymphocytes. J Infect Dis 1998; 178 (Suppl. 1): S95-s98.
23. Maloy KJ, Powrie F. Regulatory T cells in the control of immune pathology. Nat Immunol 2001; 2: 816-822.
24. Toyoda M, Hara M, Bhawan J. Epidermal innervation correlates with severity of photodamage. A quantitative ultrastructural study. Exp Dermatol 1996; 5: 260-266.
25. Danno K, Sayeed QK, Horiguchi Y, Imamura S. Ultraviolet radiation abolishes cutaneous nerve stainings with two axon-specific antibodies in guinea-pig skin. Arch Dermatol Res 1993; 284: 460-465.
26. Wallengren J, Sundler F. Phototherapy reduces the number of epidermal and CGRP-positive dermal nerve fibres. Acta Derm Venereol 2004; 84: 111-115.
27. El-Ghor AA, Norval M. Biological effects of narrow-band (311nm TL01) UVB irradiation: A review. J Photochem Photobiol B 1997; 38: 99-106.
28. Diffey BL. Factors affecting the choice of a ceiling on the number of exposures with TL01 ultraviolet B phototherapy. Br J Dermatol 2003; 149: 428-30.